SOTIO to Present Final Phase II DCVAC/OvCa Data at the 2019 SGO Annual Meeting on Women's Cancer
PRAGUE, Czech Republic, March 07, 2019 / B3C newswire / -- SOTIO, a biotechnology company owned by the PPF Group, today announces that final data from the SOV02 Clinical Trial with DCVAC/OvCa will be presented in the plenary session as an oral presentation at the 2019 SGO’s 50th Annual Meeting on Women's Cancer. Final analysis of SOV02 data confirmed promising clinical efficacy of DCVAC/OvCa in patients with the 1st recurrence of ovarian cancer.
Details for the SGO presentation are as follows:
Oral presentation at plenary session
Title: Dendritic cell-based immunotherapy (DCVAC/OvCa) with chemotherapy in patients with platinum-sensitive, relapsed, epithelial ovarian carcinoma: Survival analysis of a phase II, open-label, randomized, multicenter trial (study SOV02)
|Session:||Scientific Plenary VI: Immunotherapy: Treatment, Trials, Toxicity|
|Date and time:||Tuesday, March 19, 2019 at 7:45 am - 9:00 am|
|Presenter:||David Cibula, MD, PhD, General University Hospital (Prague, Czech Republic), Past-President of European Society of Gynaecological Oncology (ESGO), principal investigator of SOV02|
About SOV02 clinical trial
SOV02 is a randomized, open-label, parallel-group, multi-center Phase II clinical trial evaluating the effect of adding DCVAC/OvCa to standard chemotherapy (carboplatin and gemcitabine) in women with first relapse of platinum-sensitive epithelial ovarian cancer.
The SOTIO DCVAC product candidates are active cellular immunotherapy treatments which are produced individually for each patient using the patient’s own dendritic cells (which form part of the immune system) to induce an immune reaction against tumor antigens. SOTIO is developing three product candidates using the DCVAC platform to affect multiple different cancers in various stages of the disease - DCVAC/OvCa for patients with ovarian cancer, DCVAC/PCa for patients with prostate cancer and DCVAC/LuCa for patients with lung cancer.
The company is currently testing the safety and efficacy of investigational medicinal treatment DCVAC through multiple Phase I to Phase III clinical trials.
The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. SGO contributes to the advancement of women’s cancer care by encouraging research, providing education, raising standard of practice, advocating for patients and members and collaborating with international organizations. SGO has around 2000 members representing entire gynecologic oncology team on international level.
SOTIO is an international biotechnology company leading the efforts of PPF Group to build a diverse biotechnology portfolio through its own research & development, collaborations, in-licensing, investments, mergers and acquisitions. The company is developing new medical therapies, focusing on the treatment of cancer and autoimmune diseases. The most advanced project is the SOTIO proprietary platform of active cellular immunotherapy (ACI) based on dendritic cells. SOTIO is conducting multiple Phase I to Phase III clinical trials verifying the safety and efficacy of its DCVAC products. SOTIO is also collaborating with NBE Therapeutics on the development of novel antibody-drug conjugate products (ADC), with Cytune Pharma on developing novel IL15-based immunotherapies for the treatment of cancer and with LDC and the Max Planck Society on an oncology program addressing a novel target in tumor metabolism. SOTIO has facilities in Europe, the United States, China and Russia.
SOTIO is a registered trademark of SOTIO a.s. in selected countries.
Head of Communication
T: (+420) 224 174 448
M: (+420) 603 280 971
Published by B3C newswire and shared through Newronic®